Correction
for
Chwalisz et al., Endocr Rev 26 (3) 423-438.
Endocrine Reviews 26 (5): 703
Copyright © 2005 by The Endocrine Society
Erratum
The May 2005 article "Selective Progesterone Receptor Modulator Development and Use in the Treatment of Leiomyomata and Endometriosis" by K. Chwalisz, M. C. Perez, D. DeManno, C. Winkel, G. Schubert, and W. Elger (Endocrine Reviews 26:423438, 2005) contained the following errors:
On page 425, the second sentence in the paragraph subtitled "A. SPRM definition" should read as follows: Accordingly, SPRMs represent a class of PR ligands that exerts clinically relevant tissue-selective progesterone agonist, antagonist, partial, or mixed agonist/antagonist effects on various progesterone target tissues in an in vivo situation depending on the biological action studied.
On page 425, in the Leiomyoma row in Table 1, the downward arrow in the Progestins column should be removed and placed in the SPRM column. The corrected table appears below.
View this table:
[in this window]
[in a new window]
|
TABLE 1. Comparison of major pharmacodynamic effects of progestins, PAs, and SPRMs based on studies in humans and animals
|
|